




PHARMACEUTICAL 2017

Anthera Pharmaceuticals Inc
Rank 253 of 292





PHARMACEUTICAL 2017

Anthera Pharmaceuticals Inc Rank 253 of 292

The relative strengths and weaknesses of Anthera Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Anthera Pharmaceuticals Inc compared to the market average is the variable Other Expenses, increasing the Economic Capital Ratio by 29% points. The greatest weakness of Anthera Pharmaceuticals Inc is the variable Research and Development, reducing the Economic Capital Ratio by 197% points.

The company's Economic Capital Ratio, given in the ranking table, is -196%, being 199% points below the market average of 2.9%.

| Input Variable | Value in 1000 USD |
|---|-------------------|
| Assets, Current | 22,708 |
| Cost of Goods Sold | 0 |
| Intangible Assets | 0 |
| Liabilities, Current | 10,624 |
| Liabilities, Non-Current | 0 |
| Other Assets | 0 |
| Other Compr. Net Income | 0 |
| Other Expenses | -261 |
| Other Liabilities | 0 |
| Other Net Income | 1,654 |
| Other Revenues | 145 |
| Property and Equipment | 763 |
| Research and Development | 46,512 |
| Selling, General and Administrative Expense | 11,071 |

| Output Variable | Value in 1000 USD |
|--------------------------|-------------------|
| Assets | 23,471 |
| Liabilities | 10,624 |
| Expenses | 57,322 |
| Revenues | 145 |
| Stockholders Equity | 12,847 |
| Net Income | -55,523 |
| Comprehensive Net Income | -55,523 |
| Economic Capital Ratio | -196% |